Corbus Pharmaceuticals released Q2 2026 results and a corporate update, giving investors a fresh view of its financial position and execution. The biotech expec

Corbus Pharmaceuticals released Q2 2026 results and a corporate update, giving investors a fresh view of its financial position and execution. The biotech expects Phase 1b obesity data in September and has FDA clearance to start a registrational cancer study.